Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002507 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
A Phase 3 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002507: Completed Phase 3 study, sponsored by Yale University.
NCT00002507 is a Phase 3 study that has completed, run by Yale University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002507, a Phase 3 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combining mitomycin or porfiromycin with radiation therapy is more effective in treating patients with head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus either mitomycin or porfiromycin in treating patients with head and neck cancer.
Interventions
- RADIATION radiation therapy
- RADIATION brachytherapy
- DRUG mitomycin C
- DRUG porfiromycin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1992-11 |
| Est. Completion | 2002-10 |
| Phase | Phase 3 |
What the finished NCT00002507 record still lists
NCT00002507 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which radiation therapy is the first listed.
NCT00002507 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002507 about?
NCT00002507 is a clinical study titled "Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combining mitomycin or porfiromycin with radiation therapy is more effective in treatin...
What is the current status of trial NCT00002507?
This trial is currently completed. It is a Phase 3 study. The study started on 1992-11. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00002507?
The interventions under investigation include: radiation therapy (RADIATION), brachytherapy (RADIATION), mitomycin C (DRUG), porfiromycin (DRUG).
Who is sponsoring clinical trial NCT00002507?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia